is semaglutide a sglt2 inhibitor once weekly as add-on to SGLT-2 therapy in type 2 diabetes (SUSTAIN 9): randomised, placebo-controlled trial GLP-1 Receptor Agonist Therapy With

Wang L, Kounatidis I, Ligoxygakis P

Placebo: 2.4% weight reduction with 31.5% of participants achieving at least a 5% weight loss

Aside from this lack of difference between the treatment groups, the study had a high dropout rate and, as such, the generalizability of the results of the study should be interpreted with caution

Unlike traditional treatments that target only CSF production, GLP-1 agonists may work through two pathways: Weight loss - a major long-term treatment for IIH Possible CSF pressure effects - GLP-1 receptors on the choroid plexus (where CSF is made) may reduce fluid secretion independent of weight loss The IIH Pressure Trial ( Brain , 2023) found that exenatide lowered intracranial pressure within hours of the first dose

Understanding MK-677 (Ibutamoren) MK-677 differs from other GH secretagogues as an oral compound rather than injectable peptide